The actions of prolactin (PRL), a hormone utilized in normal and malignant mammary tissues, are mediated through its receptor (PRLr), a member of the cytokine receptor superfamily. PRL acts to stimulate the survival, motility, and the progression of human breast cancer. PRL-induced dimerization of the PRLr induces the association, tyrosine phosphorylation, and activation of members of the Vav family (Vav1-3) of guanine nucleotide exchange factors (GEF), an event necessary for PRL-driven cellular signaling and function. We have discovered two novel protein kinases in association with Vav1 and Vav2, namely the tyrosine kinase Tec, and the serine/threonine kinase Nek3. Both kinases are rapidly activated during PRL-stimulated signaling and associate with the PRLr-Vav2 complex in human breast cancer, forming a macromolecular signaling assembly. It is the central hypothesis of this proposal that the structures and interactions in the PRLr-Tec/Vav2/Nek3 complex coordinately activate the downstream effectors and functions associated with PRLr action. This hypothesis will be tested by three specific aims using breast cancer and PRL-responsive lines. First, the functional role of Tec and Nek3 during PRL-driven proliferation, survival, and cytoskeletal change will be assessed at the cellular and molecular levels, through the transfection of wild-type, activated, and kinase-dead forms of Tec and Nek3. Second, the location of Vav2 tyrosine phosphorylation will be determined by mass spectroscopy and the functional significance of these residues evaluated by replacement mutagenesis. Third, mutagenic and biophysical approaches will identify and characterize the interaction motifs within the PRLr-Tec/Vav2 complex, while the role of such motifs during PRLr-mediated signaling and action will be evaluated through the transfection of interaction defective mutants of the PRLr, Tec and Vav2. The structure/function studies proposed here will provide insight into the assembly of a multimeric PRLr-associated signaling complex and relate these findings to cellular processes of relevance to the pathophysiology of human breast cancer. These analyses of PRLr-associated transduction may ultimately provide the basis for novel therapeutic strategies aimed at modulating the function of the PRL/PRLr complex.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA092265-03
Application #
6634088
Study Section
Reproductive Endocrinology Study Section (REN)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2001-07-13
Project End
2006-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
3
Fiscal Year
2003
Total Cost
$249,638
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Harrington, Katherine M; Clevenger, Charles V (2016) Identification of NEK3 Kinase Threonine 165 as a Novel Regulatory Phosphorylation Site That Modulates Focal Adhesion Remodeling Necessary for Breast Cancer Cell Migration. J Biol Chem 291:21388-21406
Fang, Feng; Zheng, Jiamao; Galbaugh, Traci L et al. (2010) Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells. J Mol Endocrinol 44:319-29
Galbaugh, Traci; Feeney, Yvonne B; Clevenger, Charles V (2010) Prolactin receptor-integrin cross-talk mediated by SIRP? in breast cancer cells. Mol Cancer Res 8:1413-24
Kotsopoulos, Joanne; Tworoger, Shelley S; Campos, Hannia et al. (2010) Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 19:938-46
McHale, Kevin; Tomaszewski, John E; Puthiyaveettil, Ragunath et al. (2008) Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod Pathol 21:565-71
Swaminathan, Gayathri; Varghese, Bentley; Thangavel, Chellappagounder et al. (2008) Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. J Endocrinol 196:R1-7
Clevenger, Charles V; Zheng, Jiamao; Jablonski, Elizabeth M et al. (2008) From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia 13:147-56
Miller, S L; Antico, G; Raghunath, P N et al. (2007) Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 26:4668-78
Miller, Sommer L; DeMaria, Jamie E; Freier, David O et al. (2005) Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol Endocrinol 19:939-49
Clevenger, Charles V (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165:1449-60